Business Insider · 30 January 2024 · by Hayley Cuccinello
Business Insider examined why wealthy investors are putting money into biotech aimed at extending healthspan — the years lived free of chronic disease — rather than simply extending lifespan. The piece profiles Maximilian Winter, General Partner at Harmonix, alongside other investors who came to the field through personal experience, and weighs the field’s promise against its costs, regulatory hurdles and the unproven treatments marketed to the wealthy.
“There’s been a lot of hype around longevity. We haven’t seen a lot of it materialize.”
Maximilian Winter, quoted in Business Insider